Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7081-7089

  Nowak, Pawel ^a   Cole, Derek C ^a   Brooijmans, Natasja ^a   Bursavich, Matthew G ^a   Curran, Kevin J ^a   Ellingboe, John W ^a   Gibbons, James J ^a   Hollander, Irwin ^a   Hu, YongBo ^a   Kaplan, Joshua ^a   Malwitz, David J ^a   Toral Barza, Lourdes ^a   Verheijen, Jeroen C ^a   Zask, Arie ^a   Zhang, Wei Guo ^a   Yu, Ker ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 BENZYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 6 PYRIDIN 3 YL 1H PYRAZOLO[3,4 D]PYRIMIDINE; 1 (1 BENZYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 6 PYRIDIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDINE TRIFLUOROACETIC ACID SALT; 1 (1 BENZYLPIPERIDIN 4 YL) 6 (1 METHYL 1H INDOL 5 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDINE; 1 (1 BENZYLPIPERIDIN 4 YL) 6 (1H INDOL 2 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDINE; 1 (1 BENZYLPIPERIDIN 4 YL) 6 (1H INDOL 4 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDINE TRIFLUOROACETIC ACID SALT; 1 (1 BENZYLPIPERIDIN 4 YL) 6 (1H INDOL 6 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDINE TRIFLUOROACETIC ACID SALT; 1 (1 BENZYLPIPERIDIN 4 YL) 6 (1H INDOL 7 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDINE; 2 [1 (1 BENZYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENOL; 3 (4 MORPHOLIN 4 YL 1 PIPERIDIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL)PHENOL; 3 [1 (1 ACETYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENOL; 3 [1 (1 BENZOYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENOL; 3 [1 (1 BENZYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENOL; 3 [1 (1 BENZYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]QUINOLINE TRIFLUOROACETIC ACID SALT; 3 [4 MORPHOLIN 4 YL 1 [1 (PYRIDIN 3 YLCARBONYL)PIPERIDIN 4 YL] 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENOL; 3 [4 MORPHOLIN 4 YL 1 [1 (PYRIDIN 3 YLMETHYL)PIPERIDIN 4 YL] 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENOL; 4 (1 (1 BENZYLPIPERIDIN 4 YL) 6 (1H INDOL 5 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 YL)MORPHOLINE; 4 (6 (1H INDOL 5 YL) 1 (PIPERIDIN 4 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 YL)MORPHOLINE; 4 [1 (1 BENZYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENOL TRIFLUOROACETIC ACID SALT; 5 [1 (1 BENZYLPIPERIDIN 4 YL) 4 MORPHOLIN 4 YL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL] 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE TRIFLUOROACETIC ACID SALT; 6 (1H INDOL 5 YL) 4 MORPHOLIN 4 YL 1 [1 (PYRIDIN 3 YLCARBONYL)PIPERIDIN 4 YL] 1H PYRAZOLO[3,4 D]PYRIMIDINE; 6 (1H INDOL 5 YL) 4 MORPHOLIN 4 YL 1 [1 (PYRIDIN 3 YLMETHYL)PIPERIDIN 4 YL] 1H PYRAZOLO[3,4 D]PYRIMIDINE; 6 (1H INDOL 5 YL) 4 MORPHOLIN 4 YL 1 [1 (PYRIDIN 3 YLMETHYL)PIPERIDIN 4 YL] 1H PYRAZOLO[3,4 D]PYRIMIDINE TRIFLUOROACETIC ACID SALT; 6 [1 (1 BENZYLPIPERIDIN 4 YL) 4 (MORPHOLIN 4 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]QUINOLINE TRIFLUOROACETIC ACID SALT; BIOLOGICAL MARKER; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PYRAZOLOPYRIMIDINE DERIVATIVE; RAPAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CELL ASSAY; CRYSTAL STRUCTURE; DRUG INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MODEL; X RAY;

BINDING, COMPETITIVE; CELL LINE, TUMOR; DRUG DISCOVERY; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR WEIGHT; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 70949092751     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9012642     Document Type: Article

References (31)

1. Sarbassov, D. D.; Ali, S. M.; Sabatini, D. M. Growing roled of the mTOR pathway. Curr. Opin. Cell Biol. 2005, 17, 596-603.
2. Wullschleger, S.; Loewith, R.; Hall, M. N. TOR signaling in growth and metabolism. Cell 2006, 124, 471-484.
3. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12, 9-22.
4. Chiang, G. G.; Abraham, R. T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13, 433-442.
5. Guertin, D. A.; Sabatini, D. M. The pharmacology of mTOR inhibition. Sci. Signaling 2009, 2, 1-6.
6. Abraham, R. T. PI 3-kinase related kinases: "big" players in stress-induced signaling pathways. DNA Repair 2004, 3, 883-887.
7. Yuan, T. L.; Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27, 5497-5510.
8. Carracedo, A.; Pandolfi, P. P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27, 5527-5541.
9. Inoki, K.; Corradetti, M. N.; Guan, K. L. Dysregulation of the TSCm-TOR pathway in human disease. Nat. Genet. 2005, 37, 19-24.
10. Choi, J.; Chen, J.; Schreiber, S. L.; Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996, 273, 239-242. (Pubitemid 26285890)
11. Liang, J.; Choi, J.; Clardy, J. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 Å resolution. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1999, 55, 736-744.
12. Easton, J. B.; Houghton, P. J. mTOR and cancer therapy. Oncogene 2006, 25, 6436-6446.
13. Dancey, J. E. Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. 2006, 5, 1065-1073.
14. Abraham, R. T.; Gibbons, J. J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res. 2007, 13, 3109-3114.
15. Sarbassov, D. D.; Ali, S. M.; Kim, D. H.; Guertin, D. A.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14, 1296-1302.
16. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Rüegg, M. A.; Hall, A.; Hall, M. N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004, 6, 1122-1128
17. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A. T.; Thomas, G.; Kozma, S. C.; Papa, A.; Nardella, C.; Cantley, L. C.; Baselga, J.; Pandolfi, P. P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118, 3065-3074.
18. Sauveur-Michel, M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7, 1851-1863.
19. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Angela, H.; Bernard, N.; Sonia, A.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; De Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 2007, 67, 5840-5850.
20. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J. A.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 2008, 51, 5522-5532.
21. Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W.-G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, K.; Malwitz, D. J.; Cole, D. C.; Ellingboe, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Gibbons, J. J.; Abraham, R. T.; Nowak, P.; Zask, A. Biochemical, cellular and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69, 6232-6240.
22. Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.; Shokat, K. M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7, 371-383.
23. García-Martínez, J. M.; Moran, J.; Clarke, R. G.; Gray, A.; Cosulich, S. C.; Chresta, C. M.; Alessi, D. R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009, 421, 29-42.
24. Thoreen, C. C.; Kang, S. A.; Chang, J. W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L. J.; Sim, T.; Sabatini, D. M.; Gray, N. S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284, 8023-8032.
25. Hopkins, L. A.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431. (Pubitemid 38510559)
26. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discovery 2009, 8, 203-212.
27. http://www.invitrogen.com/kinaseprofiling.
28. Matsushita, K.; Hasegawa, H.; Kuribayashi, Y.; Ohashi, N. Preparation of Sulfonylureidopyrazole Derivatives as Endothelin Converter Enzyme Inhibitors. PCT Int. Appl. WO 9730978 A1, 1997; Sumitomo Pharmaceuticals Co., Ltd., Japan.
29. Muller, M. A.; Gaplovsky, M.; Wirz, J.; Woggon, W.-D. Synthesis and photophysical properties of a deazaflavin-bridged porphyrinatoiron(III) that mimics the interaction of a deazaflavin inhibitor with the heme-thiolate cofactor of cytochrome P450 3A4. Helv. Chim. Acta 2006, 89, 2987-3001.
30. Toral-Barza, L.; Zhang, W. G.; Lamison, C.; LaRocque, J.; Gibbons, J.; Yu, K. Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay. Biochem. Biophys. Res. Commun. 2005, 332, 304-310.
31. Zask, A.; Kaplan, J.; Toral-Barza, L.; Hollander, I.; Young, M.; Tischler, M.; Gaydos, C.; Cinque, M.; Lucas, J.; Yu, K. Synthesis and structure-activity relationship of ring-opened 17-hydroxy-wortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy. J. Med. Chem. 2008, 51, 1319-1323.